TABLE 2.
Results of the exploratory analyses for the 2020 Australian incident populations, only considering shifts from stage I to stage II (breast cancer, colorectal cancer and lung cancer) and stage T1 to stage T2 (melanoma)
| Breast Cancer | Colorectal Cancer | Lung Cancer | Melanoma | |||||
|---|---|---|---|---|---|---|---|---|
| 3 Month Delay | 6 Month Delay | 3 Month Delay | 6 Month Delay | 3 Month Delay | 6 Month Delay | 3 Month Delay | 6 Month Delay | |
| Stage Progression | ||||||||
| Probability of progression from I to II or T1 to T2 | 5.6% | 10.9% | 3.0% | 5.9% | 8.3% | 16.0% | 32.0% | 64.0% |
| % of patients who progressed | 1.4% | 5.5% | 0.7% | 2.9% | 2.1% | 8.0% | 8.0% | 32.0% |
| Health Outcomes | ||||||||
| Excess deaths after 5 years | 7 | 25 | 3 | 11 | 11 | 43 | 67 | 270 |
| Life years lost over a 5‐year time horizon | 20 | 64 | 7 | 29 | 44 | 170 | 195 | 791 |
| Life years lost over a 10‐year time horizon | 77 | 239 | 24 | 96 | 98 | 373 | 626 | 2584 |
| Economic Outcomes | ||||||||
| Incremental healthcare costs (in thousands)* | $1,981 | $7,699 | $411 | $1,619 | – | – | $9,109 | $36,436 |
*
No differences between treatment costs for stage I compared to stage II were assumed for lung cancer.